Form 4: United Therapeutics Exec Sells Shares Via 10b5-1 Plan

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock, acquired through stock options, as part of a pre-arranged 10b5-1 trading plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp., reported a transaction involving the exercise of 10,000 stock options and the subsequent sale of these shares.
• The exercise price for the stock options was $117.76 per share.
• The sale of the 10,000 shares occurred on June 15, 2026, with a weighted average sale price of $538.5233.
• This transaction was executed under a Rule 10b5-1 trading plan established on October 31, 2025, which is designed to satisfy affirmative defense conditions for insider trading.
• Following these transactions, Edgemond's beneficial ownership of United Therapeutics common stock decreased by 10,000 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While the sale by an executive could be seen negatively, the execution under a 10b5-1 plan mitigates concerns about insider trading and suggests a planned financial action rather than a reaction to negative company news.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating adherence to pre-determined trading strategies and compliance with insider trading regulations.
• The exercise of options and sale of shares at a significant profit ($538.5233 sale price vs. $117.76 exercise price) suggests a positive performance of the company's stock.

Negatives

• A significant number of shares (10,000) were sold by a key executive, which could be perceived negatively by the market, despite being part of a pre-planned strategy.

Risks

• The sale of a substantial number of shares by a high-ranking executive, even under a 10b5-1 plan, could be interpreted by the market as a lack of confidence in future stock performance.
• The weighted average sale price reflects multiple transactions, and the specific prices ranged from $537.91 to $554.09, indicating potential market volatility during the trading period.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that Form 4 filings reporting stock option exercises and sales by executives are common in the biotechnology and pharmaceutical sectors, often reflecting compensation structures and personal financial planning. The execution of these trades under a 10b5-1 plan is a standard practice to mitigate insider trading concerns.

Stakeholder Impact

• Shareholders: May perceive the sale by a key executive as a negative signal, despite the 10b5-1 plan, potentially impacting short-term stock sentiment.
• Employees: Similar to shareholders, may interpret the sale as a sign of reduced executive confidence, although the planned nature of the sale may temper this.
• Management: The use of a 10b5-1 plan reinforces adherence to corporate governance best practices regarding insider trading.

Next Steps

• The reporting person will provide further information upon request regarding the specifics of the transactions.
• Continued monitoring of subsequent Form 4 filings from United Therapeutics executives for any further significant transactions.

Key Dates

Keywords

United Therapeutics, UTHR, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Share Sale, CFO, Treasurer, Beneficial Ownership